XML 92 R79.htm IDEA: XBRL DOCUMENT v3.25.0.1
Development, Commercialization and Supply Agreement - Additional Information (Detail) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2024
Jun. 30, 2024
Jan. 31, 2024
Oct. 31, 2023
Jul. 31, 2023
Jan. 31, 2023
Jan. 31, 2022
Jan. 31, 2020
Dec. 31, 2019
Sep. 30, 2018
Sep. 30, 2017
Mar. 31, 2017
Mar. 31, 2016
Feb. 28, 2015
Jun. 30, 2024
Dec. 31, 2023
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2018
Jan. 10, 2024
Feb. 28, 2023
License And Collaboration Agreements [Line Items]                                              
Revenue recognized related to upfront and milestone payments                             $ 4,900   $ 18,500 $ 4,850          
Revenue recognized related to upfront and milestone payments                                     $ 18,586        
Licenses revenue                                   228,614 306,911 $ 369,193      
Deferred revenue                               $ 4,850   0 4,850 15,346      
Product Revenue, Net                                              
License And Collaboration Agreements [Line Items]                                              
Licenses revenue                                   204,590 285,299 $ 366,511      
Achievement of REDUCE-IT Trial                                              
License And Collaboration Agreements [Line Items]                                              
Revenue recognized related to upfront and milestone payments                               2,500              
Marine                                              
License And Collaboration Agreements [Line Items]                                              
Revenue recognized related to upfront and milestone payments                                 3,900            
Mochida Pharmaceutical Co., Ltd. | In-licenses                                              
License And Collaboration Agreements [Line Items]                                              
Milestones payment     $ 1,000     $ 1,000 $ 1,000                                
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense                                              
License And Collaboration Agreements [Line Items]                                              
Up-front payment                                         $ 2,700    
Edding                                              
License And Collaboration Agreements [Line Items]                                              
Revenue recognized related to upfront and milestone payments                             $ 4,000   5,000            
Edding | Achievement of REDUCE-IT Trial | VASCEPA                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable milestone payment received   $ 15,000                                          
Edding | Out-licenses                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable up-front received                           $ 15,000                  
Sales-based milestone event payment                                   120,000          
Revenue recognized related to upfront and milestone payments [1]                                     12,913        
Revenue recognized related to upfront and milestone payments [1]                                   19,426          
Deferred revenue                               4,400     4,400        
Edding | Out-licenses | Licensing Revenue                                              
License And Collaboration Agreements [Line Items]                                              
Licenses revenue                                   40,081 20,655        
Edding | Out-licenses | Product Revenue, Net                                              
License And Collaboration Agreements [Line Items]                                              
Licenses revenue                                   16,000 1,800        
Edding | Out-licenses | Maximum                                              
License And Collaboration Agreements [Line Items]                                              
Sales-based milestone event payment                                   50,000          
Edding | Out-licenses | Minimum                                              
License And Collaboration Agreements [Line Items]                                              
Sales-based milestone event payment                                   5,000          
Edding | Out-licenses | Clinical Trial Application                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable milestone payment received                         $ 1,000                    
Edding | Out-licenses | Achievement of REDUCE-IT Trial                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable milestone payment received       $ 3,000                                      
Edding | Out-licenses | Marine                                              
License And Collaboration Agreements [Line Items]                                              
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                                 3,900            
Additional license revenues                               5,000   4,000 5,000        
Revenue recognized related to upfront and milestone payments                                   15,000          
Remaining performance period amount                               $ 1,100     1,100        
Reduction in net loss                                   4,000 $ 5,000        
Edding | Out-licenses | Marine | VASCEPA                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable milestone payment received                       $ 5,000                      
Edding | Out-licenses | Marine | Maximum                                              
License And Collaboration Agreements [Line Items]                                              
Revenue recognition period of non-refundable up-front payment                                     3 years        
Edding | Out-licenses | Marine | Minimum                                              
License And Collaboration Agreements [Line Items]                                              
Revenue recognition period of non-refundable up-front payment                                     11 years        
Biologix FZCo                                              
License And Collaboration Agreements [Line Items]                                              
Revenue recognition period of non-refundable up-front payment                                     8 years        
Biologix FZCo | Out-licenses                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable milestone payment received                                     $ 5,300        
Reduction in net loss                                     5,300        
Biologix FZCo | Out-licenses | Product Revenue, Net                                              
License And Collaboration Agreements [Line Items]                                              
Licenses revenue                                   2,700 3,400        
HLS                                              
License And Collaboration Agreements [Line Items]                                              
Revenue recognized related to upfront and milestone payments                                 $ 5,300            
HLS | Out-licenses                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable up-front received                     $ 5,000                        
Non-refundable milestone payment received               $ 3,800                              
Revenue recognized related to upfront and milestone payments                                     5,600        
HLS | Out-licenses | Health Canada                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable milestone payment received                 $ 2,500                            
HLS | Out-licenses | Product Revenue, Net                                              
License And Collaboration Agreements [Line Items]                                              
Licenses revenue                                   4,700 3,100        
HLS | Out-licenses | Maximum                                              
License And Collaboration Agreements [Line Items]                                              
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                     $ 50,000                        
HLS | Out-licenses | Achievement of REDUCE-IT Trial                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable milestone payment received                   $ 2,500                          
CSL Seqirus | Out-licenses                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable up-front received $ 500                                            
Non-refundable milestone payment received $ 1,200                                            
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone                                           $ 1,200  
Licenses revenue                                   1,200 500        
Upfront payment receivable                                             $ 500
Event-related milestone payments receivable                                           6,000  
Additional product-related milestone payments receivable                                           $ 4,000  
CSL Seqirus | Out-licenses | Product Revenue, Net                                              
License And Collaboration Agreements [Line Items]                                              
Licenses revenue                                   800 0        
Lotus Pharmaceuticals | VAZKEPA                                              
License And Collaboration Agreements [Line Items]                                              
Non-refundable up-front received         $ 300                                    
Upfront payment receivable         $ 300                                    
Lotus Pharmaceuticals | Out-licenses | Licensing Revenue                                              
License And Collaboration Agreements [Line Items]                                              
Licenses revenue                                   $ 0 $ 300        
[1] Licensing revenue under the DCS Agreement is recognized concurrent with the input measure of support hours provided by Amarin to Edding in achieving the combined development and regulatory performance obligation, which in the Company’s judgment is the best measure of progress towards satisfying this performance obligation.